4.8 Article

Mesoporous ZnO nanocapsules for the induction of enhanced antigen-specific immunological responses

Journal

NANOSCALE
Volume 9, Issue 38, Pages 14641-14653

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/c7nr03697c

Keywords

-

Funding

  1. Department of Biotechnology, Government of India [BT/PR8624/MED/29/798/2013]
  2. Department of Science and Technology, Government of India [DST] [SB/YS/LS-163/2013, SR/FTP/ETA-0079/2011]
  3. Department of Science and Technology, Nanomission, Government of India [DST] [SR/NM/NS-1040/2013(G)]
  4. University Grants Commission, Government of India [UGC] [MRP-MAJOR-BIOT-2013-40689]

Ask authors/readers for more resources

The application of nanotechnology in vaccinology has fuelled rapid advancement towards the design and development of nanovaccines. Nanoparticles have been found to enhance vaccine efficacy through the spatiotemporal orchestration of antigen delivery to secondary lymphoid organs and antigen-presentation by Antigen Presenting Cells (APCs) synchronized with stimulation of innate and adaptive immune responses. Metal based nanoparticles (MNPs) have been extensively engineered for the generation of nanovaccines owing to their intrinsic adjuvant-like properties and immunomodulatory functions. Furthermore, mesoporous nanocapsules of late have attracted researchers due to their precise size and exclusive capacity to encapsulate a wide range of biomolecules and their sustained release at the targeted sites. Herein, we have designed a novel mesoporous ZnO nanocapsule (mZnO) having a size of similar to 12 nm with an average pore diameter of 2.5 nm, using a surfactant-free sonochemical method and investigated its immunomodulatory properties by using Ova loaded mZnO nanocapsules [mZnO(Ova)] in a mice model. Our findings show that mZnO(Ova) administration steered the enhanced expansion of antigenspecific T-cells and induction of IFN-gamma producing effector CD4(+) and CD8(+) T-cells. Also, antigen-specific IgG levels were enriched in both the serum and lymph nodes of mZnO(Ova) immunized mice. Further, we noticed a substantial increase in serum IgG2a or IgG2b levels and IFN-gamma secretion in Ova restimulated splenocytes from mZnO(Ova) immunized mice, indicating that mZnO(Ova) skew Th1 type immune response. Overall, the uniqueness of mZnO nanocapsules in terms of the defined particle to pore numbers ratio (maximum of three cavities per particle) allows loading antigens efficiently. Given these features in combination with its immunomodulatory characteristics reinforces the idea that mZnO could be used as an effective antigen-adjuvant platform for the development of novel nano-based vaccines against multiple diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available